drug · small molecule
patient view →entrectinib
Marketedupdated 2mo agoby F. Hoffmann-La Roche Ltd🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and non-small cell lung carcinoma and 6 investigational indications.
indications
investigational
NSCLC
targets
ALK tyrosine kinase receptorNeurotrophic tyrosine kinase receptorProto-oncogene tyrosine-protein kinase ROS
all catalysts(0)
nothing on the calendar yet
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that